Enliven Therapeutics (NASDAQ:ELVN) Given New $40.00 Price Target at Robert W. Baird

Enliven Therapeutics (NASDAQ:ELVN) had its target price upped by Robert W. Baird from $32.00 to $40.00 in a report published on Friday morning,Benzinga reports. They currently have an outperform rating on the stock.

Separately, HC Wainwright reissued a “buy” rating and issued a $37.00 price objective on shares of Enliven Therapeutics in a research note on Tuesday, October 1st.

Enliven Therapeutics Price Performance

ELVN stock opened at $24.41 on Friday. The company’s 50-day moving average is $26.28 and its 200-day moving average is $23.98. The stock has a market capitalization of $1.15 billion, a PE ratio of -12.85 and a beta of 1.08. Enliven Therapeutics has a 1 year low of $9.80 and a 1 year high of $30.03.

Insider Transactions at Enliven Therapeutics

In other news, CEO Samuel Kintz sold 12,000 shares of the firm’s stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $22.89, for a total value of $274,680.00. Following the transaction, the chief executive officer now owns 1,049,255 shares in the company, valued at $24,017,446.95. This trade represents a 1.13 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Benjamin Hohl sold 6,250 shares of the company’s stock in a transaction on Monday, October 28th. The stock was sold at an average price of $28.56, for a total value of $178,500.00. The disclosure for this sale can be found here. Insiders sold a total of 152,195 shares of company stock valued at $4,091,454 over the last three months. Corporate insiders own 29.20% of the company’s stock.

Institutional Trading of Enliven Therapeutics

Several institutional investors have recently made changes to their positions in ELVN. FMR LLC boosted its holdings in Enliven Therapeutics by 10.6% during the third quarter. FMR LLC now owns 6,296,179 shares of the company’s stock worth $160,804,000 after purchasing an additional 601,611 shares during the last quarter. First Turn Management LLC bought a new position in shares of Enliven Therapeutics during the 2nd quarter worth approximately $9,657,000. Janus Henderson Group PLC boosted its stake in shares of Enliven Therapeutics by 43.0% in the 3rd quarter. Janus Henderson Group PLC now owns 1,041,724 shares of the company’s stock worth $26,611,000 after buying an additional 313,019 shares during the last quarter. Ally Bridge Group NY LLC purchased a new position in shares of Enliven Therapeutics in the 3rd quarter worth approximately $5,998,000. Finally, Marshall Wace LLP bought a new position in shares of Enliven Therapeutics in the second quarter valued at approximately $4,489,000. Institutional investors own 95.08% of the company’s stock.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.